Searched for
CHECKPOINT THERAPEUTICS
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...- Sun Pharma shares jump over 9% after firm announces $12 billion Organon acquisitionSun Pharmaceutical Industries' shares surged after announcing the $11.75 billion acquisition of US-based Organon & Co., a global leader in ...
- Sun Pharma shares tumble 4% as firm closes in on $12-billion Organon acquisition. What’s spooking investors?Shares of Sun Pharmaceutical Industries fell sharply after ET reported the company had submitted a $12-billion binding offer for Organon & ...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Sun Pharma places non-binding offer for US-based Organon in its boldest global bet everSun Pharmaceutical Industries Ltd has submitted a non-binding offer to acquire US-based Organon for an all-cash deal, securing $10-14 billi...
- Sun Pharma looks to rise in US with $10 billion Organon buyIndia's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based Organon, a sp...
- Biotech breakthrough? INKT stock skyrockets 530% after cell therapy cures testicular cancerMiNK Therapeutics made headlines after its stock soared over 500% when one patient with advanced testicular cancer was completely cured usi...
- New launches to drive Sun Pharma’s future growth; PAT may take a hit by tax surgeSun Pharma anticipates revenue growth for fiscal year 26, building on an 8% increase in fiscal year 25. However, increased spending on mark...
- Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapyThe deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...
- Sun Pharma lines up $100 mn to commercialise niche products this fiscalSun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its spe...
- JM Financial retains Buy on Sun Pharma, lowers target price to Rs 2,025JM Financial maintains a Buy call on Sun Pharmaceutical Industries, setting a revised target price of Rs 2025. Sun Pharma's Q4FY25 results ...
- Pharma & healthcare deals see shifting focus on scalable, global models: Grant Thornton BharatIndia's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal volumes and a ...
- Stocks to buy today: IndusInd Bank gets a downgrade; Motilal Oswal sees over 20% upside in Sun PharmaNuvama has downgraded IndusInd Bank to "Reduce" citing concerns over internal derivative trades and management changes, while Antique remai...
- Sun Pharma shares in focus as co to acquire Checkpoint Therapeutics for $355 millionSun Pharmaceutical announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, an immunotherapy and oncology company. The deal invo...
- Sun Pharmaceuticals to acquire Checkpoint Therapeutics for $355 mnSun Pharmaceuticals will acquire Checkpoint Therapeutics for $355 million, bringing the FDA-approved anti-PD-L1 treatment for advanced cuta...
- US to reclassify cannabis as low-risk drug, in major shiftThe US attorney general sent a proposal to the White House on Tuesday to "reclassify marijuana," Justice Department spokesperson Xochitl Hi...
- Moderna cancer vaccine trial begins in UK, scientists hopeful of 'dawn of a new age of treatments'Cancer patients in the UK are part of a global trial for the mRNA therapy mRNA-4359. The phase 1/2 clinical trial, sponsored by Moderna, ai...
- Glenmark receives DCGI nod to conduct clinical trials of its molecule on cancer patientsThe Mumbai-based drug major said, GRC 54276 has shown tumor cell killing ability in preclinical studies as a single agent and as well in co...
- Jubilant Life signs $180 mn outlicensing deal with Checkpoint"The pact includes an upfront payment of $2 mn and contingent pre-clinical, clinical and regulatory payments including commercials up to $1...
Load More
